Weikang Pharmaceutical: The acceptance of the application for listing of Vitamin K1 drops will not affect the performance in the near future.

On the evening of July 21, Weikang Pharmaceutical announced in a stock trading abnormality notice that, after self-inspection, the company did not violate the regulations regarding fair information disclosure. The company has received a notice of acceptance for the listing application of Vitamin K1 drops, which will not affect the company's recent performance. The time and results of obtaining the registration approval for the related drug are uncertain.